以我国54家中药上市公司为研究对象，利用其2012—2016年面板数据，选取11个财务指标，采用因子分析法构建中药上市公司成长性评价指标体系，在此基础上采用Topsis法，计算中药上市公司综合因子得分与最优解贴近度，进一步分析各中药上市公司成长性。研究结果表明，我国约79.63%的中药上市公司综合因子得分与最优解贴近度分布在0.4～0.7，说明我国中药上市公司成长性有较大提升空间；仅3.7%的中药上市公司综合因子得分与最优解贴近度分布在0.8～0.9，我国中药上市公司并未发挥其龙头作用。最后为促进我国中药公司健康发展提出相关政策建议。

Using 54 traditional Chinese medicine (TCM) listed companies in China as a research sample, panel data of 54 companies from 2012 to 2016 was used, the 11 financial indicators was selected to build a Chinese medicine listed companies growth evaluation index system by the factor analysis method. On this basis, Topsis method was used to calculate the comprehensive factor of TCM listed companies and the optimal solution of the closeness degree, in order to analyze the growth of TCM listed companies. The results showed that about 79.63% of TCM listed companies' comprehensive factor score and the optimal solution of the close degree near the distribution from 0.4 to 0.7, indicating that the growth of TCM listed companies have a greater room for improvement; Only 3.7% of TCM listed companies comprehensive factor score and the optimal solution near the distribution from 0.8 to 0.9. China's TCM listed companies did not play its leading role. Finally, this paper puts forward relevant policy suggestions for promoting the healthy development of TCM companies.

国家中药材产业技术体系（CARS-21）；国家自然科学基金资助项目“集中度对乳品供应链垂直协作影响的理论与实证研究”（71573098）；中央高校基本科研业务费专项资助项目（2662016PY072）；华中农业大学人文社科优秀人才培养计划基金（52206-008034）